Can Glimepiride improve outcomes in patients with non-alcoholic fatty liver disease (NAFLD)? How does it address insulin resistance and inflammation in this condition?
Lakshya KumarExplorer
Can Glimepiride improve outcomes in patients with non-alcoholic fatty liver disease?
Share
Glimepiride, primarily for diabetes, may indirectly benefit NAFLD by enhancing insulin sensitivity, thus reducing liver fat and inflammation.